➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Moodys
McKesson
Harvard Business School
McKinsey

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 9,211,304

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,211,304
Title:Therapy-enhancing glucan
Abstract: This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.
Inventor(s): Cheung; Nai-Kong V. (New York, NY), Engstad; Rolf Einar (Tromoso, NO)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY) BIOTEC PHARMACON ASA (Oslo, NO)
Application Number:13/760,307
Patent Claims:see list of patent claims

Details for Patent 9,211,304

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Sloan-Kettering Institute for Cancer Research (New York, NY) BIOTEC PHARMACON ASA (Oslo, NO) 2023-07-16 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Sloan-Kettering Institute for Cancer Research (New York, NY) BIOTEC PHARMACON ASA (Oslo, NO) 2023-07-16 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Sloan-Kettering Institute for Cancer Research (New York, NY) BIOTEC PHARMACON ASA (Oslo, NO) 2023-07-16 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Sloan-Kettering Institute for Cancer Research (New York, NY) BIOTEC PHARMACON ASA (Oslo, NO) 2023-07-16 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Sloan-Kettering Institute for Cancer Research (New York, NY) BIOTEC PHARMACON ASA (Oslo, NO) 2023-07-16 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Sloan-Kettering Institute for Cancer Research (New York, NY) BIOTEC PHARMACON ASA (Oslo, NO) 2023-07-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
AstraZeneca
McKesson
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.